Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 January 2022 | Story Rulanzen Martin | Photo Charl Devenish
The Free State once again excelled in the NSC matric results. Pictured here is a broadcast of a celebratory event held by the FSDoE on the UFS South Campus in 2021 for the matric class of 2020.

The Free State has claimed the top spot in the National Senior Certificate (NSC) examination results for the third consecutive year, with a pass rate of 85,7% in 2021. 

“On behalf of the executive management, staff, and students of the University of the Free State (UFS), I would like to extend our warmest congratulations to you and your executive team on the Free State being the top-achieving province,” Prof Francis Petersen, UFS Rector and Vice-Chancellor, wrote in a congratulatory letter to Dr Tate Makgoe, MEC for Education in the Free State. 

“The UFS is proud to be associated with the Free State Department of Education and we salute you and your team for the many initiatives in schools across the province, which have contributed to the outstanding matric results this year,” Prof Petersen said. 

The UFS will welcome several first-year students on its three campuses in February – many of whom hail from schools in the Free State. The 2021 NSC results were released on 20 January 2022. 
 
Several UFS-led interventions thrive to make impactful change 

The UFS is leading several projects with the Department of Education to address education-related problems in the province. The UFS, through its South Campus, presents the In-Service (InSET) programme, the Internet Broadcast Project (IBP), and the Schools Partnership Project. “It is projects such as these that make a huge difference in the lives of many learners and teachers in our province and that have given so many schools the opportunity to rise to the occasion,” Prof Petersen said. 

The IBP supports learners from 80 schools, with lessons for learners in Grades 8 to 12 being transmitted to three centres across the Free State on a daily basis. Electronic access to learning material is also made possible through the IBP. The Schools Partnership Project, as part of the Social Responsibility Project at the UFS, is focused on the efficacy and quality of school management, subject teaching, and learning development. Well-trained mentors visit project schools on a daily basis, sharing knowledge, materials, and demonstrating the use of technology in an effort to improve the standard of teaching. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept